Chimerix Q3 2023 Earnings Report $2.81 -0.10 (-3.44%) (As of 12/17/2024 ET) Earnings HistoryForecast Chimerix EPS ResultsActual EPS-$0.27Consensus EPS -$0.22Beat/MissMissed by -$0.05One Year Ago EPSN/AChimerix Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.22 millionBeat/MissMissed by -$210.00 thousandYoY Revenue GrowthN/AChimerix Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AConference Call ResourcesPress ReleaseCMRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Chimerix Earnings HeadlinesWedbush Has Pessimistic Outlook of Chimerix Q4 EarningsDecember 15 at 1:41 AM | americanbankingnews.comHC Wainwright Has Positive Estimate for Chimerix Q4 EarningsDecember 15 at 1:07 AM | americanbankingnews.comTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.December 18, 2024 | Banyan Hill Publishing (Ad)Wedbush Comments on Chimerix's Q2 Earnings (NASDAQ:CMRX)December 14, 2024 | americanbankingnews.comEdward White’s Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA PlansDecember 11, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Earns Outperform Rating from WedbushDecember 11, 2024 | americanbankingnews.comSee More Chimerix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chimerix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chimerix and other key companies, straight to your email. Email Address About ChimerixChimerix (NASDAQ:CMRX), a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.View Chimerix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
